Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / RLYB - Rallybio sees positive results in phase 1 trial of complement-mediated diseases candidate

RLYB - Rallybio sees positive results in phase 1 trial of complement-mediated diseases candidate

Rallybio Corporation

  • Rallybio ( NASDAQ: RLYB ) reported positive phase 1 top-line results for its complement-mediated diseases candidate RLYB116.
  • In the study, a single, 1mL subcutaneous injection of 100 mg of RLYB116 led to a reduction in free C5 more than 99% within 24 hours of dosing.
  • RLYB116 is an of inhibitor of the protein complement component 5 (C5).
  • RLYB116 was observed to be generally well-tolerated with no serious adverse events reported.
  • Rallybio ( RLYB ) released its Q3 2022 earnings earlier Monday morning .

For further details see:

Rallybio sees positive results in phase 1 trial of complement-mediated diseases candidate
Stock Information
Company Name: Rallybio Corporation
Stock Symbol: RLYB
Market: NASDAQ
Website: rallybio.com
Menu
RLYB RLYB Quote RLYB Short RLYB News RLYB Articles RLYB Message Board
Get RLYB Alerts

News, Short Squeeze, Breakout and More Instantly...